NGS-Guided Treatment Strategy Shows Promise for STK11/KEAP1-Mutated NSCLC Patients
Key Insights
Next-generation sequencing of STK11 (search) and KEAP1 (search) mutations emerges as a crucial biomarker for guiding treatment decisions in non-small cell lung cancer, potentially improving patient outcomes through personalized therapy selection.
Clinical data demonstrates significantly reduced survival in NSCLC (search) patients with STK11 (search) or KEAP1 (search) mutations when treated with standard immunotherapy, highlighting the need for alternative treatment approaches.
The POSEIDON trial reveals promising results for triple combination therapy with durvalumab, tremelimumab, and chemotherapy in STK11 (search)/KEAP1 (search)-mutated NSCLC (search), offering new hope for this difficult-to-treat patient population.
Recent findings presented at the 22nd Annual Winter Lung Cancer Conference highlight the growing importance of next-generation sequencing (NGS) in guiding treatment decisions for non-small cell lung cancer (NSCLC (search)) patients, particularly those with mutations in STK11 (search) and KEAP1 (search) genes.
Dr. Ferdinandos Skoulidis, associate professor at The University of Texas MD Anderson Cancer Center, emphasized the critical role of comprehensive NGS panels in treatment selection. "We normally do not use checkpoint blockade in patients with EGFR mutations or ALK rearrangements. I would argue that we should be also taking into consideration the whole NGS panel, especially in patients [with mutations] in 2 genes: STK11 (search) and KEAP1 (search)."
Impact of Genetic Mutations on Treatment Response
STK11 (search) alterations significantly correlate with reduced PD-L1 (search) expression in tumor cells, while KEAP1 (search) loss of function mutations, occurring in 10-15% of NSCLC (search) patients, affect critical cellular pathways. Both mutations contribute to an immunosuppressive tumor microenvironment, potentially explaining their impact on treatment outcomes.
A comprehensive retrospective study revealed striking differences in survival outcomes based on mutation status. Patients with KRAS-mutated/STK11 (search) wild-type disease showed a median overall survival of 17.3 months compared to just 6.2 months in those with KRAS-mutated/STK11-mutated disease. Similar patterns were observed with KEAP1 (search) mutations.
Novel Treatment Approaches Show Promise
The phase 3 POSEIDON trial demonstrated encouraging results for patients with STK11 (search)- and/or KEAP1 (search)-mutated NSCLC (search). The trial evaluated durvalumab with or without tremelimumab in combination with chemotherapy. Patients receiving the triple combination achieved a median overall survival of 15.8 months, significantly better than the 7.3 months observed with the doublet therapy.
TRITON Trial: Confirming the Path Forward
Building on these findings, the newly launched phase 3b TRITON study aims to definitively compare the efficacy of tremelimumab-durvalumab-chemotherapy combination against the current standard pembrolizumab-chemotherapy regimen. The trial, which began enrollment in April 2024, specifically targets patients with STK11 (search), KEAP1 (search), or KRAS mutations.
"STK11 (search) and KEAP1 (search) may represent emerging biomarkers for the selection of first-line regimens, and the current data suggest the selective benefit for the addition of doubling checkpoint blockade," Dr. Skoulidis concluded, highlighting the potential for more personalized treatment approaches in NSCLC (search).